<DOC>
	<DOCNO>NCT01090895</DOCNO>
	<brief_summary>Primary Hypothesis : Prophylactic Vitamin C Intravenous Infusion time percutaneous coronary intervention ( PCI ) would limit size infarct , assess measurement cardiac biomarkers , acute myocardial infarction . Secondary Hypotheses : Prophylactic Vitamin C Intravenous Infusion time percutaneous coronary intervention ( PCI ) would limit size infarct , measure area delay hyperenhancement see cardiac magnetic resonance imaging ( MRI ) , assess day 5 infarction , acute myocardial infarction .</brief_summary>
	<brief_title>Treatment Reperfusion Event Vitamin C Infusion</brief_title>
	<detailed_description>This multicenter , prospective , control , randomize study conduct 5 center Italy . All patient meet eligibility criterion randomize receive surgical procedure intravenous infusion Vitamin C Placebo . Patients repeat clinical follow-up 5 day , 3 6 month 1 year . The new angiography evaluation do necessary . The study population consist least 100 patient present within 12 hour onset chest pain , ST-segment elevation 0.1 mV two contiguous lead , clinical decision make treat percutaneous coronary intervention ( PCI ) . Following confirmation eligibility criterion , patient randomize 1:1 ratio receive prophylactic infusion Vitamin C Placebo . The coronary angiogram assess core laboratory Quantitative Coronary Angiography . The incidence clinical event , include death , myocardial infarction , target vessel revascularization , stent thrombosis , evaluate 1 , 3 , 6 , 12 month .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Subjects present within 12 hour onset chest pain , STsegment elevation 0.1 mV two contiguous lead , clinical decision make treat percutaneous coronary intervention ( PCI ) Patients eligible study whether undergo primary PCI . Signed write informed consent Patients cardiac arrest , ventricular fibrillation , cardiogenic shock , stent thrombosis , previous acute myocardial infarction , angina within 48 hour infarction include study Patients evidence coronary collateral ( 23 Rentrop ) region risk initial coronary angiography ( time admission ) exclude The patient impair renal function ( creatinine &gt; 3.0 mg/dl ) The patient know allergy aspirin , clopidogrel bisulfate ticlopidine , heparin , contrast medium stainless steel manage medically The patient need therapy warfarin The patient life expectancy le 12 month Recipient heart transplant The patient currently participate investigational drug another device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Vitamin C</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Magnetic Risonance</keyword>
</DOC>